Merck Mevacor Pediatric Exclusivity Gets July 3 Hearing; 5 Generics Stayed
Executive Summary
The D.C. federal court is scheduled to hear arguments on Merck's Mevacor pediatric exclusivity application July 3.
You may also be interested in...
Amgen’s Challenge Over Sensipar Pediatric Exclusivity Moves To US Appeals Court
Amgen asserts FDA improperly tied pediatric exclusivity denial to lack of meaningful labeling resulting from the studies; justices question whether Amgen's data were adequate to support exclusivity but also agency's public silence on how it decides when a sponsor has 'fairly responded' to a written request.
Pediatric Studies: Must Sponsors Meet Every Detail Of US FDA Request To Get Exclusivity?
In suit against FDA, Amgen argues it provided sufficient data to obtain exclusivity for Sensipar but agency says too few patients were included in one study; court ruled against FDA in similar 2001 dispute.
FDA Quality Of Life Guidance Receives Renewed Interest After Industry Input
FDA has renewed development of a guidance on the use of quality of life claims in drug labeling and promotional materials after gathering input from industry